Help Save Lives And Make A Fortune Doing It
By Ray Blanco | May 22, 2017 |

The all-stars in cancer research are once again set to ascend upon the picturesque city of Chicago in June.

The marquee event bringing in this elite force of cancer warriors is the 53rd annual meeting for the American Society of Clinical Oncology (ASCO)...

And the innovations expected from this year’s conference could revolutionize the biotech landscape for years to come.

This of course means huge opportunity for you.

I mean just imagine... being able to fund breakthrough cancer research, and at the same time potentially rake in tons of cash.

It’s the true definition of a potential "win-win".

A Rising Tide Lifts All Boats...
As you know markets move up, markets move down. They can prop up weak stocks or bury strong ones. As it stands, investors are very optimistic about biotech right now.

Overall biotech is having a great 2017 so far. The Nasdaq Biotechnology Index is up over 10% and the small-cap S&P Biotechnology Select Industry Index is up over 17%.

That’s all well and great, yet for biotech traders, the overall market isn’t actually the most important factor to watch when making investment decisions.

Years of trading biotech have proven to me that no other sector of the market moves as independently of the overall market as small development-stage biotechs do.

And these moves can be very fast.

---Sponsored Link---

Donald Trump… The Best President EVER?
They said Trump would only help the top 1%… But he’s already helping everyday Americans get rich. What you’re about to see could cement Trump’s legacy as the greatest president EVER. Click here to see what’s STUNNING liberals across the country.

Even in a down market, a small little known biotech can go from zero to hero overnight.

Why? The biotech industry has a number of high profile events that we can track to make big gains -- over and over again.

And it works in both good markets and bad.

These events include much more than earnings reports. They include clinical trial results, FDA decisions, commercialization schedules, and marquee conferences.

And a positive outcome from one of these events can be worth more than gold.

It’s event specific catalysts that matter most when investing in biotech. Events like the upcoming ASCO annual meeting taking place over the first week in June.

It's The World's Biggest Cancer Shindig
The ASCO meetings are some of the most pivotal meetings of cancer warriors that take place all year... And anyone who’s someone in cancer research will be there.

Many cancer researchers will be spending days presenting scientific results. This includes a great many biotechnology companies -- and this is where we can profit.

In-depth data from a clinical trial can really put an upward move on a small biotech...

And if a biotech is undervalued enough, it doesn't take much to put you on a path to big gains.

And The Next Big Thing Is...
I've uncovered two biotech companies with exceptionally unique and potentially game-changing breakthroughs that will be presenting at this year's conference.

The first company, Syndax Pharmaceuticals Inc., has an advanced cancer treatment currently in Phase III trials. The treatment is so highly touted that it earned the FDA’s coveted "Breakthrough Therapy" designation while in Phase II trials.

If the FDA is saying it’s a breakthrough, then you MUST keep watch!

The second company I am watching closely is TG Therapeutics. The company is releasing its Phase III trial results at this year’s meeting and has the potential to change the biotech landscape significantly.

I’m talking about a treatment that could have an immediate impact on how doctors treat lymphoma and lyphomatic leukemia... potentially saving thousands of lives.

Of course these aren’t the only two companies presenting at ASCO. We'll be watching ASCO developments closely over the coming weeks and months.

And as news continues to trickle out, I will be right here to make sure you have the info you need to capitalize on the next big thing in biotech.

This article originally appeared on The Daily Reckoning.